) announced positive interim results from an ongoing phase I
study (n=34) of SAR566658. The results were presented at the
AACR-NCI-EORTC International Conference on Molecular Targets and
SAR566658 is being developed for the treatment of ovarian,
breast, and other epithelial cancer forms. Data from the study
revealed that SAR566658 was generally well tolerated. Moreover,
the data showed that SAR566658 was capable of inducing objective
responses and sustained stable disease in heavily pre-treated
patients suffering from CA6-positive cancer.
ImmunoGen mentioned in its press release that limited adverse
events normally associated with cytotoxic chemotherapy was
observed during the study. The candidate was evaluated at doses
bet 10-240 mg/m2 in this portion of the study for 3 weeks. The
recommended dosage was identified as 190. SAR566658 is now being
assessed at the recommended dose in the extension phase of the
ImmunoGen has an agreement with
) for the development of SAR566658, and the initiation of
clinical testing. SAR566658 has been developed using ImmunoGen's
Targeted Antibody Payload (TAP) technology. Two more compounds,
SAR3419 and SAR650984, developed through the TAP technology, are
currently in clinical trials, also in collaboration with Sanofi.
SAR3419 is currently in a phase II study being developed for the
treatment of non-Hodgkin lymphoma. Meanwhile, SAR650984 is
currently being developed in a phase I study for the treatment of
blood cancer including multiple myeloma.
We are encouraged by ImmunoGen's association with companies of
the likes Sanofi and
Eli Lilly and Company
). The company is expected to ink more deals in the future for
further pipeline development.
ImmunoGen presently carries a Zacks Rank #3 (Hold). Meanwhile,
stocks such as
) look better positioned with a Zacks Rank #1 (Strong Buy).
ACTELION LTD (ALIOF): Get Free Report
IMMUNOGEN INC (IMGN): Free Stock Analysis
LILLY ELI & CO (LLY): Free Stock Analysis
SANOFI-AVENTIS (SNY): Free Stock Analysis
To read this article on Zacks.com click here.